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Abstract
Background: A dengue virus type 2 (DEN-2 Tonga/74) isolated from a 1974 epidemic was
characterized by mild illness and belongs to the American genotype of DEN-2 viruses. To prepare
a vaccine candidate, a previously described 30 nucleotide deletion (∆30) in the 3' untranslated
region of DEN-4 has been engineered into the DEN-2 isolate.
Methods: A full-length cDNA clone was generated from the DEN-2 virus and used to produce
recombinant DEN-2 (rDEN-2) and rDEN2∆30. Viruses were evaluated for replication in SCID
mice transplanted with human hepatoma cells (SCID-HuH-7 mice), in mosquitoes, and in rhesus
monkeys. Neutralizing antibody induction and protective efficacy were also assessed in rhesus
monkeys.
Results: The rDEN2∆30 virus was ten-fold reduced in replication in SCID-HuH-7 mice when
compared to the parent virus. The rDEN-2 viruses were not infectious for Aedes mosquitoes, but
both readily infected Toxorynchites mosquitoes. In rhesus monkeys, rDEN2∆30 appeared to be
slightly attenuated when compared to the parent virus as measured by duration and peak of viremia
and neutralizing antibody induction. A derivative of rDEN2∆30, designated rDEN2∆30-4995, was
generated by incorporation of a point mutation previously identified in the NS3 gene of DEN-4 and
was found to be more attenuated than rDEN2∆30 in SCID-HuH-7 mice.
Conclusions: The rDEN2∆30 and rDEN2∆30-4995 viruses can be considered for evaluation in
humans and for inclusion in a tetravalent dengue vaccine.
Background
The increased prevalence of disease caused by the mos-
quito-borne dengue (DEN) viruses (four serotypes; DEN-
1 – DEN-4) has intensified the effort to generate a vaccine
that would both confer protection and be economically
feasible for use in countries with limited resources for
healthcare [1]. Dengue fever and dengue hemorrhagic
fever and shock (DHF/DSS) are a severe disease burden
for tropical and semitropical countries inhabited by more
than 2.5 billion people [2]. Risk factors for the more
severe disease, DHF/DSS, include the strain of virus, age
and genetic background of the host, and secondary
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infection by a DEN serotype different from that which
caused the primary infection [2]. Increased risk associated
with secondary infection by a different DEN serotype is
believed to be caused both by increased virus replication
resulting from antibody-dependent enhancement and by
augmented immune activation induced by the secondary
infection [3,4]. Typically, regions with DHF/DSS have all
four DEN serotypes circulating simultaneously, and an
effective DEN vaccine must contain a tetravalent formula-
tion that confers protection against each of the four DEN
serotypes.
Immunity to the DEN viruses is primarily mediated by
neutralizing antibodies directed against the envelope (E)
glycoprotein, and most vaccine strategies aim to induce
antibody against this major protective antigen. Live atten-
uated tetravalent vaccines appear to be the best vaccine
candidates since they are economical to manufacture and
they induce long-term immunity with the live attenuated
yellow fever virus vaccine serving as a successful model
flavivirus vaccine [5]. Several strategies to produce live
attenuated tetravalent vaccines are being pursued includ-
ing attenuation of viruses by conventional passage in tis-
sue culture or introduction of defined attenuating
mutations into recombinant DEN viruses [6-9]. In addi-
tion, chimeric dengue viruses are being evaluated that
contain the E protein of a DEN virus on a background of
either an attenuated DEN virus from a different serotype
or a more distantly related, but attenuated, flavivirus [10-
12].
We have previously described attenuated and immuno-
genic monovalent vaccine candidates for DEN-1, DEN-2,
DEN-3, and DEN-4 that were generated by two distinct
recombinant methodologies. Using the first methodol-
ogy, nucleotides 10478–10507 were deleted from the 3'
UTR (∆30) of a wild type cDNA clone for DEN-4 to gener-
ate a vaccine candidate, rDEN4∆30, which is safe, attenu-
ated, and immunogenic in rhesus monkeys and humans
[13]. Incorporation of the ∆30 mutation into an infec-
tious cDNA clone of DEN-1 wild type virus at a site
homologous to that in DEN-4 attenuated DEN-1 for rhe-
sus monkeys and is currently being evaluated in humans
[14]. The ∆30 mutation did not confer attenuation upon
DEN-3 for reasons that have not been defined [15]. Thus,
this approach has yielded live attenuated virus vaccine
candidates for both DEN-1 and DEN-4. Using a second
methodology, antigenic chimeric viruses have been gener-
ated by replacing the membrane protein (M) and E struc-
tural genes of rDEN4∆30 with those from DEN-2 or DEN-
3 [12,15]. These antigenic chimeric viruses were attenu-
ated and immunogenic in rhesus monkeys and represent
vaccine candidates for DEN-2 and DEN-3. We have also
described a set of point mutations that can attenuate wild
type rDEN-4 for SCID mice transplanted with human liver
cells (SCID-HuH-7) or for rhesus monkeys [16,17]. Such
mutations identified in rDEN-4 could be introduced into
conserved sites of cDNA clones for other DEN serotypes to
fine-tune the level of attenuation of vaccine candidates.
We have found it prudent to pursue several strategies to
develop a live attenuated virus vaccine for each dengue
serotype recognizing that it has been a challenge to
achieve a satisfactory balance between attenuation and
immunogenicity [15,18-20]. Thus, in addition to the anti-
genic chimeric DEN-2 vaccine candidate described above,
a second approach was pursued in the present study that
involved the construction of an infectious cDNA clone of
a wild type DEN-2 virus isolated in Tonga [21], and the
generation of DEN-2 vaccine candidates by the sequential
introduction of defined attenuating mutations into the
recombinant version of the DEN-2 Tonga/74 wild type
virus. The rDEN2∆30 vaccine candidate was evaluated for
replication in SCID-HuH-7 mice, mosquitoes, and rhesus
monkeys. In addition, an attenuating point mutation, pre-
viously described in DEN-4, was introduced into the
rDEN2∆30 virus, and this rDEN2∆30 derivative was char-
acterized in SCID-HuH-7 mice.
Methods
Cells and viruses
Vero cells (African green monkey kidney) were propa-
gated in OptiPro SFM (Invitrogen, Grand Island, NY) sup-
plemented with 4 mM L-glutamine (Invitrogen). HuH-7
cells (human hepatoma) were maintained in D-MEM/F-
12 (Invitrogen) supplemented with 10% fetal bovine
serum (FBS), 1 mM L-glutamine and 0.05 mg/ml gen-
tamicin (Invitrogen). C6/36 cells (Aedes albopictus mos-
quito cells) were maintained at 32°C in Minimal Essential
Medium (MEM) containing Earle's salts and 25 mM
HEPES buffer (Invitrogen) and supplemented with 10%
FBS, 2 mM L-glutamine, and 0.1 mM non-essential amino
acids (Invitrogen).
A dengue virus type 2 isolate, Tonga/74, was provided by
Dr. Duane Gubler (CDC, Fort Collins, CO). The virus was
isolated during a 1974 dengue outbreak in the South
Pacific island of Tonga [21]. The virus was isolated by
inoculation of patient sera into Aedes albopictus mosqui-
toes, and subsequent passage in C6/36 cells before deter-
mination of genomic sequence.
Sequence analysis
Viral RNA was isolated from DEN-2 Tonga/74 wild type
virus using the QIAamp Viral RNA mini kit (Qiagen,
Valencia, CA). Reverse transcription was performed using
random hexamer primers and the SuperScript First-Strand
Synthesis System for RT-PCR (Invitrogen). Overlapping
PCR fragments of approximately 2000 base pairs were
generated using DEN-2 specific primers and AdvantageBMC Infectious Diseases 2004, 4:39 http://www.biomedcentral.com/1471-2334/4/39
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cDNA polymerase (ClonTech, Palo Alto, CA). Both
strands of the resulting PCR fragments were sequenced
directly on a 3100 Genetic Analyzer (Applied Biosystems,
Foster City, CA) using DEN-2 specific primers in BigDye
terminator cycle sequencing reactions (Applied Biosys-
tems) and the results were assembled into a consensus
sequence. To determine the nucleotide sequence of the
genomic 5' and 3' regions, the 5' cap nucleoside of the
viral genome was removed with tobacco acid pyrophos-
phatase (Epicentre Technologies, Madison, WI), followed
by circularization of the genome using RNA ligase (Epi-
centre Technologies). An RT-PCR fragment spanning the
ligation junction was generated and sequenced using
DEN-2 primers. For the DEN-2 Tonga/74 consensus
sequence, GenBank accession number AY744147 was
assigned.
Genetic construction of rDEN-2 Tonga/74 cDNA clone
cDNA fragments of DEN-2 Tonga/74 were generated by
reverse-transcription of the genome as indicated in Figure
1. Each fragment was subcloned into a plasmid vector and
sequenced to verify that it matched the consensus
sequence as determined for the virus. This yielded seven
cloned cDNA fragments spanning the genome. Cloned
fragments were modified as follows: Fragment X, repre-
senting the 5' end of the genome was abutted to the SP6
promoter; Fragment L was modified to contain a SpeI
restriction site at genomic nucleotide 2353; Fragment R
was modified to contain a SpeI restriction site also at
genomic nucleotide 2353, and, to stabilize the eventual
full-length clone, two additional mutations at nucleotides
2362 – 2364 and 2397 were created to ensure that trans-
lation stop codons were present in all reading frames
other than that used to synthesize the virus polyprotein;
Fragment A was modified at nucleotide 3582 to ablate a
naturally occurring SpeI restriction site and at nucleotide
4497 to ablate a naturally occurring KpnI restriction site;
Fragment C was modified at nucleotide 9374 to ablate a
naturally occurring KpnI restriction site; and Fragment Y,
representing the 3' end of the genome was abutted to a
KpnI restriction site. All mutations introduced into the
cloned cDNA fragments were translationally-silent,
thereby preserving the wild-type polyprotein sequence.
Each fragment was added incrementally between the AscI
and KpnI restriction sites of DEN-4 cDNA clone p4 (Gen-
Bank accession number: AY648301) to generate a full-
length DEN-2 cDNA clone (p2) with the same vector
background successfully used to generate rDEN-4 and
rDEN4∆30 virus [13]. cDNA clone p2 was sequenced to
confirm that the virus genome region matched the DEN-2
Tonga/74 consensus amino acid and nucleotide sequence,
with the exception of the translationally-silent modifica-
tions noted above. The ∆30 mutation which removes
nucleotides 10541–10570 was introduced into Fragment
Y to generate Fragment Y∆30. To create p2∆30, the Frag-
ment Y region of p2 was replaced with Fragment Y∆30
(Figure 1). The genomic region of each full-length cDNA
was sequenced as described above and GenBank acces-
sions were assigned as follows (cDNA clone: accession
numbers): p2: AY744148, p2∆30: AY744149.
Using site-directed mutagenesis, an attenuating amino
acid change characterized in the NS3 gene of DEN-4 (nt
4995–7; a.a. 158, Ser→Leu) was introduced into the
p2∆30 cDNA clone [17]. A mutagenic oligonucleotide
was designed to change DEN-2 NS3 amino acid 158 from
Ser (AGT) to Leu (CTA) and used to construct the cDNA
clone, p2∆30-4995 (accession number: AY744150),
which was sequenced for confirmation of nucleotide
changes.
Recovery of rDEN-2 viruses
cDNA clones were linearized with Acc65I (isoschizomer
of KpnI which cleaves leaving only a single 3' nucleotide)
and were transcribed in vitro using the AmpliCap SP6 Mes-
sage Maker kit (Epicentre Technologies, Madison, WI).
Purified transcripts were then transfected into Vero or C6/
36 cells. Viruses recovered in C6/36 cells were passaged 3
times in Vero cells, and all viruses were biologically
cloned by terminal dilution in Vero cells. The genomes of
recombinant viruses used to infect rhesus monkeys were
completely sequenced as described above to identify
adventitious mutations that had accumulated during
transfection and biological cloning.
Replication in SCID-HuH-7 mice
Four to six week-old SCID mice (Tac:Icr:Ha(ICR)-Prkdcs-
cid) (Taconic, Germantown, NY) were injected intraperito-
neally with 107  HuH-7 cells suspended in 0.2 ml
phosphate-buffered saline. Tumors were detected in the
peritoneum, and mice were infected by direct inoculation
of the tumor with 104 PFU of virus in 0.05 ml Opti-MEM
(Invitrogen). On day 7 post-infection, serum was
obtained from cardiac blood and stored at -70°C. Virus
titer in serum samples was determined by plaque assay in
Vero cells.
Replication, immunogenicity, and protection in rhesus 
monkeys
The DEN-2 viruses were evaluated in rhesus macaques
using established methods [13]. DEN virus sero-negative
monkeys were injected subcutaneously with 105 PFU virus
diluted in L-15 medium (Invitrogen) or with a mock inoc-
ulum. Serum was collected on days 0–6, 8, 10, 12 and 28
after inoculation and stored at -70°C. Virus titer was
determined for each serum sample by plaque assay in
Vero cells and serum neutralizing antibody titer was deter-
mined for serum from days 0 and 28 by plaque reduction
neutralization test. On day 28, monkeys were challenged
with 105  PFU of DEN-2 Tonga/74, and serum wasBMC Infectious Diseases 2004, 4:39 http://www.biomedcentral.com/1471-2334/4/39
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collected on days 29–34, 36, and 56. Virus titer was deter-
mined for serum from days 28–34 and 36 and serum neu-
tralizing antibody titer was determined for serum from
day 56.
Virus replication in mosquitoes
Replication in Aedes aegypti and Toxorynchites amboinensis
mosquitoes was evaluated as previously described [22].
Briefly, A. aegypti were fed blood meals containing serial
10-fold dilutions of virus. After 21 days, viral antigen was
detected in head and midgut preparations by immuno-
flourescence assay using DEN-2-specific hyperimmune
mouse ascitic fluid and fluorescein isothyocyanate conju-
gated goat anti-mouse IgG (KPL, Gaithersburg, MD), and
the mosquito infectious dose-50% (MID50) was deter-
mined. T. amboinensis were inoculated intrathoracically
with a 0.2 ul dose containing serial ten-fold dilutions of
virus and incubated for 14 days. Head preparations were
made and antigen visualized as described above.
Results
Generation and sequence analysis of recombinant DEN-2 
Tonga/74 viruses
A full-length cDNA clone, p2, was constructed that
matched the genomic consensus sequence of the Ameri-
can genotype DEN-2 isolate, Tonga/74, with the exception
Molecular construction of the DEN-2 full-length cDNA plasmids p2 and p2∆30 Figure 1
Molecular construction of the DEN-2 full-length cDNA plasmids p2 and p2∆30. A. Diagram of the complete full-
length DEN-2 Tonga/74 cDNA plasmid p2 is shown annotated with the restriction enzyme and corresponding cleavage site 
locations used to assemble the subcloned RT-PCR fragments. Restriction enzyme cleavage sites are numbered relative to 
nucleotide position in the virus genome. The corresponding genomic regions encoded by each subcloned RT-PCR fragment, X, 
L, R, A, B, C, and Y, are shown above the plasmid diagram. Relative positions of the SP6 promoter and tetracycline resistance 
gene (Tetr) are indicated. B. To generate plasmid p2∆30, 30 nucleotides are removed from the 3'-UTR (Fragment Y). The 
nucleotide sequence encompassing the ∆30 region is shown for the p2 parent cDNA and the resulting p2∆30 cDNA. Nucle-
otide positions in the virus genome are indicated for p2.
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of translationally-silent modifications made to facilitate
cloning (Figure 1). The previously described ∆30 deletion
mutation was incorporated into the p2 cDNA clone to
form p2∆30 [13]. The rDEN-2 virus was recovered in C6/
36 and Vero cells, but the presence of the ∆30 mutation
limited recovery to only C6/36 cells. After passage in Vero
cells, adaptation mutations were identified by sequence
analysis as had been described for other DEN viruses [23].
Both rDEN-2 and rDEN2∆30 viruses accumulated a single
nucleotide change in NS4B at nt 7169 encoding a
Val→Ala change at amino acid position 115 as has been
observed for rDEN-3 (Table 1) [15]. The same nucleotide
change was previously reported to occur at the homolo-
gous site following passage of DEN-4 in Vero cells result-
ing in a Leu→Ser change (Table 1) [23]. Inclusion of the
7169 mutation into the p2∆30 cDNA permitted recovery
in both C6/36 and Vero cells (data not shown). The
rDEN2∆30 virus reached a virus titer of 6.6 log10PFU/ml
in Vero cells.
Replication of rDEN-2 viruses in SCID-HuH-7 mice
As an initial evaluation of replication of the DEN-2
Tonga/74 virus and the rDEN-2 viruses, replication in
SCID mice transplanted with HuH-7 human hepatoma
cells (SCID-HuH-7 mice) was tested. Wild-type viruses
from each DEN serotype have been shown to replicate to
approximately 6.0 log10PFU/ml serum in SCID-HuH-7
mice, and an att phenotype in SCID-HuH-7 mice has been
shown to be a predictor of reduced replication in rhesus
monkeys [12,14,15,17]. The parent DEN-2 Tonga/74
virus replicated efficiently in SCID-HuH-7 mice and
reached a mean titer in serum of 5.9 log10PFU/ml (Table
2) similar to that previously observed with the DEN-2
New Guinea C (NGC) prototype strain [12]. The rDEN-2
virus replicated to the same level as the wild-type isolate,
while rDEN2∆30 was 10-fold restricted in replication.
This reduction was statistically significant (Tukey-Kramer
post-hoc test; P < 0.05), and was similar to that observed
for the well-characterized rDEN4∆30 virus [17].
Replication of rDEN-2 viruses in mosquitoes
The DEN-2 viruses were evaluated for infectivity of Aedes
aegypti fed on an infectious bloodmeal (oral infectivity
only) and for Toxorynchites amboinensis inoculated
intrathoracically (Table 3). At the doses tested neither
DEN-2, rDEN-2, or rDEN2∆30 were detected in the
midgut or head of A. aegypti mosquitoes which had fed on
an infectious bloodmeal 21 days earlier. The inability to
infect the midgut led to a lack of infection in the head tis-
sue. This indicates that the DEN-2 Tonga/74 viruses are
poorly infectious for A. aegypti mosquitoes by oral infec-
tivity, as has been demonstrated for multiple DEN-2
viruses of the American genotype [24,25]. In contrast the
DEN-2 NGC prototype strain, an Asian genotype member,
was highly infectious in A. aegypti mosquitoes when tested
previously but it was not included here as a concurrent
control [12].
The defect in rDEN-2 infectivity for A. aegypti was further
investigated by directly inoculating the same virus stocks
intrathoracically into T. amboinensis and measuring the
ability of the viruses to infect the head tissues. Both rDEN-
2 and rDEN2∆30 were highly infectious by intrathoracic
inoculation (Table 3). The ∆30 mutation did not alter the
infectivity of rDEN-2 following intrathoracic inoculation,
Table 1: Missense and UTR mutations which arose spontaneously in rDEN-2 and rDEN2∆30 viruses during passage in Vero cells.
Virus Gene Nucleotide position Nucleotide 
substitution
Amino acid positiona Amino acid change
rDEN-2 NS4B 7169b U > C 115 Val > Ala
NS5 9248 A > C 560 Glu > Ala
rDEN2∆30 NS4B 7169b U > C 115 Val > Ala
rDEN2∆30-4995 NS3 4949 A > G 143 Lys > Arg
NS4B 7169b U > C 115 Val > Ala
3' UTR 10322 G > A -- --
a Amino acid position in the individual DEN-2 protein.
b Nucleotide position 7169 in DEN-2 corresponds to nt 7162 in rDEN-4, and the wild-type amino acid is Val and Leu, respectively [23].
Table 2: Addition of the ∆30 mutation to rDEN-2 decreases 
replication in SCID-HuH-7 mice by 10-fold.
Replication in SCID-HuH-7 micea
Virus No. of mice Mean virus titer (log10PFU/ml ± SE)
DEN-2 Tonga/74 6 5.9 ± 0.3
rDEN-2 7 5.9 ± 0.2
rDEN2∆30 9 4.9 ± 0.2
a Groups of HuH-7-SCID mice were inoculated directly into the 
tumor with 104 PFU virus. Serum was collected on day 7 and tittered 
in Vero cells.BMC Infectious Diseases 2004, 4:39 http://www.biomedcentral.com/1471-2334/4/39
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a property also previously observed for DEN-1, -3 and -4
[14,15,22]. These results indicate that the lack of infectiv-
ity for A. aegypti was likely caused by the inability of the
DEN-2 Tonga/74 viruses to establish a midgut infection
and that the viruses retained the ability to infect head
tissues.
Replication, immunogenicity, and protective efficacy in 
rhesus monkeys
The replication (viremia), immunogenicity, and protec-
tive efficacy of the DEN-2 viruses in monkeys were stud-
ied. Monkeys inoculated with the DEN-2 Tonga/74 wild-
type isolate were viremic for an average of 4.5 days with a
mean peak titer of 2.1 log10PFU/ml (Table 4). Inoculation
with rDEN-2 resulted in detectable viremia for 4.0 days
with a mean peak titer of 1.9 log10PFU/ml. While the lev-
els of rDEN2∆30 replication (2.8 days viremia; mean peak
titer of 1.7 log10PFU/ml) were lower than DEN-2 and
rDEN-2, the differences were not as dramatic as had been
observed for rDEN1∆30 and rDEN4∆30 when compared
to their parent viruses [13,14]. The level of neutralizing
antibodies induced by the rDEN2∆30 virus was also less
than that induced by the wild-type DEN-2 viruses, a
finding consistent with the decreased replication exhib-
ited by this vaccine candidate. Therefore, by three quanti-
tative measures, duration and peak titer of viremia and the
level of neutralizing antibodies induced, rDEN2∆30
appeared to be attenuated when compared to DEN-2
Tonga/74. When vaccinated monkeys were challenged
with DEN-2 Tonga/74, all monkeys were protected, as
indicated by the lack of viremia (Table 4).
The 4995 mutation further attenuates rDEN2∆30 in SCID-
HuH-7 mice
Based on the limited attenuation conferred upon rDEN-2
by the ∆30 mutation in rhesus monkeys, we sought to
construct a further attenuated derivative of rDEN2∆30. To
further attenuate rDEN2∆30, an att  mutation that has
been characterized in another DEN serotype was
imported into a homologous region in DEN-2. One such
mutation, the 4995 mutation in DEN-4 NS3 at amino
acid 158 (Ser→Leu), was previously incorporated into the
DEN-4 vaccine candidate, rDEN4∆30, and found to fur-
ther attenuate the virus for SCID-HuH-7 mice and rhesus
monkeys [17]. Site directed mutagenesis was used to
introduce a Ser→Leu mutation at amino acid 158 of NS3
in rDEN2∆30-7169, and the rDEN2∆30-4995 virus was
recovered in C6/36 cells and propagated in Vero cells
reaching a virus titer of 6.2 log10PFU/ml (Table 1). Impor-
tantly, the resulting Leu codon would require two nucle-
otide changes to revert to one of the six odons encoding a
Ser residue.
Replication in the SCID-HuH-7 mouse model was used as
an initial assessment of the rDEN2∆30-4995 virus pheno-
type. Table 5 includes results from three separate experi-
Table 3: DEN-2 Tonga/74 is poorly infectious for Aedes aegypti fed an infectious bloodmeal, and the ∆30 mutation does not decrease 
infectivity for Toxorynchites amboinensis.
A. aegypti (oral infection) T. amboinensis (intrathoracic inoculation)
Virus Dose (log10PFU)a No. tested % Infectedb Dose (log10PFU)c No. tested % Infectedd
Midgut Head
DEN-2 Tonga/74 2.8 20 0 0 -- -- --
rDEN-2 3.5 18 0 0 2.9 5 100
1.9 12 83
0.9 8 63
-0.1 7 14
-1.1 7 0
MID50 = 0.9
rDEN2∆30 3.5 22 0 0 2.7 8 100
1.7 7 100
0.7 6 83
-0.3 7 43
-1.3 4 50
-2.3 5 0
MID50 = -0.2
a Amount of virus ingested, assuming a 2 ul bloodmeal.
b Percentage of mosquitoes with antigen detectable by IFA in midgut or head tissue prepared 21 days after oral infection.
c Amount of virus present in 0.22 ul inoculum.
d Percentage of mosquitoes with antigen detectable by IFA in head tissue prepared 14 days post-inoculation.BMC Infectious Diseases 2004, 4:39 http://www.biomedcentral.com/1471-2334/4/39
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ments (including those from Table 1) and confirms the
approximate 10-fold reduction in replication conferred by
the  ∆30 mutation upon rDEN-2 replication in SCID-
HuH-7 mice. The rDEN2∆30-4995 virus had a mean peak
virus titer of 4.6 log10PFU/ml which was only a modest
reduction from that of rDEN2∆30, 5.2 log10PFU/ml.
However, comparison of a large number of samples indi-
cated that the reduction in virus titer conferred by the NS3
4995 mutation upon rDEN2∆30 was statistically signifi-
cant (rDEN2∆30-4995 versus rDEN2∆30; Tukey-Kramer
post-hoc test; P < 0.05). The virus titer of rDEN2∆30-4995
virus in SCID-HuH-7 mice was over 60-fold reduced from
that of the rDEN-2 parent virus.
Discussion
Development of a live-attenuated tetravalent dengue vac-
cine has been complicated by two major factors. First,
monovalent vaccine candidates that exhibit a satisfactory
balance between attenuation and immunogenicity have
been difficult to identify [15,18-20]. Second, satisfactorily
attenuated tetravalent vaccine formulations that induce a
broad neutralizing antibody response against each of the
four DEN serotypes have been difficult to develop
[6,10,20,26]. For these reasons, we have sought to
develop multiple vaccine candidates for each DEN sero-
type to increase the likelihood that a vaccine with a satis-
factory balance between attenuation and immunogenicity
will be identified. To produce a live-attenuated DEN-2
vaccine candidate, we previously generated an antigenic
chimeric virus, rDEN2/4∆30, expressing the M and E
structural genes of the DEN-2 NGC strain on the attenu-
ated rDEN4∆30 background [12]. The vaccine candidates
described in the present study, rDEN2∆30 and
rDEN2∆30-4995, could serve as alternates to this
antigenic chimeric virus if evaluation of the rDEN2/4∆30
virus in humans, either as a monovalent vaccine or as a
component of a tetravalent vaccine, indicates that it lacks
a balance between attenuation and immunogenicity.
It was hoped that each of the four components of a tetrav-
alent vaccine, consisting of DEN-1, -2, -3, and -4 wild type
viruses, each with the common 30 nucleotide deletion
mutation in the 3' UTR, would exhibit a similar level of
attenuation in animal models [13-15]. Unfortunately, the
level of attenuation conferred by the ∆30 mutation upon
each of the four serotypes has proven to be variable. In
rhesus monkeys, the rDEN2∆30 virus appears to have an
intermediate attenuation phenotype in between that of
the attenuated rDEN1∆30 and rDEN4∆30 and the non-
attenuated rDEN3∆30 [13-15]. Although rDEN2∆30 was
Table 4: Replication and immunogenicity of DEN-2 viruses in rhesus monkeys
Virusa % with viremia Mean no. of 
viremic days per 
monkeyb
Mean peak virus 
titer (log10PFU/ml 
± SE)
Geometric mean 
serum neutralizing 
antibody titer on day 
28 (reciprocal dilution)c
Virus replication after challenged
% with viremia Mean peak virus titer 
(log10PFU/ml ± SE)
Mock 0 0 <0.7 <10 100 2.1 ± 0.1
DEN-2 Tonga/74 100 4.5 2.1 ± 0.3 311 0 <0.7
rDEN-2 100 4.0 1.9 ± 0.1 173 0 <0.7
rDEN2∆30 100 2.8 1.7 ± 0.2 91 0 <0.7
a Groups of rhesus monkeys (mock: n = 2; viruses: n = 4) were inoculated subcutaneously with 105 PFU of the indicated virus in a 1 ml dose. Serum 
was collected daily for day 0 to 6; day 8, 10, 12 and 28
b Virus titer in serum was determined by plaque assay in Vero cells. The lower limit of detection was 0.7 log10PFU/ml. Viremia was not detected in 
any monkey after day 6.
c Plaque reduction (60%) neutralizing antibody titers were determined using DEN-2 Tonga/74. Limit of detection was < 1:10. All monkeys 
inoculated with virus had a four-fold or greater increase in neutralizing antibody titer.
d Vaccinated rhesus monkeys were inoculated subcutaneously with 105 PFU of DEN-2 Tonga/74 virus in a 1 ml dose. Serum was collected daily for 
day 0 to 8.
Table 5: Addition of the 4995 mutation further attenuates 
rDEN2∆30 in SCID-HuH-7 mice.
Replication in SCID-HuH-7 micea
Virus No. of mice Mean virus titer (log10PFU/ml ± SE)
DEN-2 Tonga/74 6 5.9 ± 0.3
rDEN-2 15 6.4 ± 0.2
rDEN2∆30 22 5.2 ± 0.1
rDEN2∆30-4995 28 4.6 ± 0.2
a Groups of HuH-7-SCID mice were inoculated directly into the 
tumor with 104 PFU virus. Serum was collected on day 7 and titered 
in Vero cells. Data is included from three separate experiments.BMC Infectious Diseases 2004, 4:39 http://www.biomedcentral.com/1471-2334/4/39
Page 8 of 10
(page number not for citation purposes)
slightly attenuated compared to its DEN-2 parent virus in
rhesus monkeys, the reduction in replication was less than
that of rDEN1∆30 and rDEN4∆30. While the latter two
viruses had detectable viremia in only 50% of monkeys, a
mean number of viremic days of less than one day, and a
mean peak viremia of less than 1.0 log10PFU/ml [13,14],
the rDEN2∆30 virus infected 100% of the rhesus monkeys
and reached a peak virus titer of 1.7 log10PFU/ml. How-
ever, the 10-fold reduction of replication of rDEN4∆30
and rDEN2∆30 in SCID-HuH-7 mice, compared to that of
their respective wild type parents, was similar. To date,
rDEN4∆30 is the only ∆30 vaccine candidate that has
been tested in humans, and it was found to be both safe
and immunogenic [13]. If the level of attenuation in
SCID-HuH-7 mice serves as a better guide to attenuation
in humans, rDEN2∆30 might be satisfactorily attenuated
in humans since its level of attenuation for SCID-HuH-7
mice and that of the rDEN4∆30 vaccine candidate are
comparable.
To construct a further attenuated derivative of rDEN2∆30,
the 4995 mutation present in the NS3 gene of DEN-4 at
amino acid 158 (Ser→Leu) was introduced into the
homologous region of the NS3 protein of rDEN2∆30
[17]. Although the 4995 mutation results in a single
amino acid change and thus may be susceptible to rever-
sion, the mutant leucine codon selected for insertion into
rDEN2∆30-4995 would require two nucleotide changes
to revert to a serine codon. Introduction of the 4995
mutation into rDEN4∆30 resulted in a 100-fold greater
reduction of replication in SCID-HuH-7 mice [17]. In
rDEN2∆30, its introduction resulted in nearly a 10-fold
reduction in virus titer, a smaller but still statistically sig-
nificant reduction. These results provide a second exam-
ple of the difficulty in predicting the precise level of
attenuation following import of an attenuating mutation
into a different DEN serotype. Nevertheless, the
rDEN2∆30-4995 vaccine candidate is more attenuated
than its rDEN2∆30 parent and warrants evaluation in rhe-
sus monkeys and humans.
Epidemiologic and molecular pathogenesis studies of
DEN-2 strains support the concept that the DEN-2 Tonga/
74 virus, from which the vaccine candidates were derived,
may naturally have a lower level of virulence than other
DEN-2 viruses. If the DEN-2 Tonga/74 parent virus is nat-
urally attenuated to some degree, only a small incremen-
tal increase in attenuation might be required to
satisfactorily attenuate it for humans. Gubler et al. inves-
tigated the 1974 outbreak of DEN-2 infection in the
Pacific island of Tonga [21]. In comparison to a subse-
quent DEN-1 outbreak, the 1974 DEN-2 outbreak was
distinguished by mild disease with few hemorrhagic
sequelae, low viremia, and an overall slow spread of virus
infection [21]. The weak DEN-2 outbreak was proposed to
be a result of the circulation of a strain with an inherently
low level of virulence [21].
Since the Tonga/74 outbreak, additional evidence has
emerged that supports the suggestion that there are at least
two circulating lineages of DEN-2 viruses that differ in vir-
ulence [27-29]. The DEN-2 Tonga/74 virus is a member of
the DEN-2 American genotype, which as a group appear
to possess lower virulence than that of the Asian genotype
of DEN-2 viruses [28,29]. Despite the presence of the
American DEN-2 genotype viruses and limited co-circula-
tion of DEN-1 and DEN-3 viruses in the Americas in the
1960s and 1970s, the first major epidemic of DHF/DSS in
the Americas occurred only after the introduction of a
DEN-2 Asian genotype virus in 1981 [27-30]. It was
thought that genetic differences might have contributed to
this difference in virulence and evidence to this effect has
been forthcoming. Rico-Hesse and colleagues have
defined genetic elements within the genome of DEN-2
American genotype viruses which distinguish them from
members of the Asian genotype [31]. In addition, using
chimeric rDEN-2 American/Asian viruses, introduction of
three genetic elements (a point mutation in the E gene,
the 5' UTR, and the 3' UTR) of the American genotype was
found to confer reduced virus replication in dendritic cells
and monocytes upon an Asian genotype rDEN-2 [32]. The
Tonga/74 virus shares each of these three attenuating
genetic determinants specific to the American genotype
[31,32], which provides a possible explanation for its
lower virulence in humans. The rDEN2∆30 vaccine candi-
date, whose parent is the DEN-2 Tonga/74 American gen-
otype virus, thus contains naturally occurring and
experimentally introduced attenuating mutations. Thus,
the small incremental increase in attenuation provided by
the ∆30, with or without the 4995 mutation, might prove
to satisfactorily attenuate the DEN-2 Tonga/74 for
humans.
The American genotype DEN-2 viruses exhibit decreased
infectivity for Aedes mosquitoes in comparison to Asian
DEN-2 viruses [24,25]. Consistent with these observa-
tions, the wild type New Guinea C Asian DEN2 virus was
highly infectious for Aedes mosquitoes in our laboratory
[12] whereas the Tonga/74 American genotype virus was
poorly infectious by the oral route (present study). In fact,
the increased prevalence of DEN-2 viruses of the Asian
genotype in the Americas has been suggested to be a result
of their enhanced transmission [28]. However, the active
circulation of American genotype viruses over many dec-
ades indicates that mosquito transmission does occur and
large epidemics have been associated with viruses of this
genotype [21,27]. At the doses tested, neither the DEN-2
Tonga/74 isolate nor the recombinant viruses were found
to infect the midgut or head of Aedes aegypti mosquitoes
fed an infectious blood meal. Since rDEN-2 andBMC Infectious Diseases 2004, 4:39 http://www.biomedcentral.com/1471-2334/4/39
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rDEN2∆30 viruses were infectious by intrathoracic inocu-
lation of Toxorynchites mosquitoes, the lack of infectivity
for A. aegypti was likely caused solely by the inability of
the DEN-2 Tonga/74 viruses to establish a midgut infec-
tion. Decreased infectivity for Aedes  mosquitoes could
serve to help limit transmission of the vaccine virus.
Conclusions
The live-attenuated DEN-2 virus candidates described
here, rDEN2∆30 and rDEN2∆30-4995, have several prop-
erties desired in a live attenuated virus vaccine for
humans. First, both viruses reached a titer over 6.0
log10PFU/ml in Vero cells that would permit economical
manufacture. Second, the viruses are derived from the
DEN-2 Tonga/74 strain, a member of the American geno-
type, which has been associated with decreased virulence.
Third, rDEN2∆30 was attenuated for replication in SCID-
HuH-7 mice and slightly attenuated for rhesus monkeys
while inducing a protective neutralizing antibody
response. Fourth, rDEN2∆30-4995 was more attenuated
in SCID-HuH-7 mice than rDEN2∆30. Fifth, the DEN-2
Tonga/74 strain, like other members of the American gen-
otype, is poorly infectious for Aedes aegypti mosquitoes
which would help to limit uncontrolled transmission of
the vaccine virus.
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